NCT01457560已完成3 期
Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Mixed With Hib Vaccine in Healthy Infants, Followed by a Dose of the Same Vaccine Administered Simultaneously With One Dose of Oral Polio Vaccine (OPV)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 80
- 主要终点
- Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values
研究概览
简要总结
This study will assess the immunogenicity and safety of the GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') combined DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine administered in the 3rd, 5th, 11th month of life. The last dose of DTPa-HBV-IPV/Hib will be given simultaneously with one dose of OPV vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 12 Weeks 至 16 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The inclusion criteria will be checked at study entry. If any of these criteria does not apply, the subject is not eligible for inclusion in the study.
- •Healthy male and female subjects in the ≥12 and <16 weeks of life at the time of the first vaccination.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Written informed consent obtained from the parents/guardians of the infant after they have been advised of the risks and benefits of the study in a language which they clearly understood, and before performance of any study procedure.
排除标准
- •The exclusion criteria will be checked at study entry and at each following visit. If any of these criteria applies at study entry, the subject is not eligible for inclusion in the study. If any of these criteria becomes applicable during the study, the subject should be withdrawn.
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Administration of chronic immunosuppressants or other immune-modifying drugs within three months before vaccination).
- •Administration of a vaccine not foreseen by the study within 30 days before each dose of the study vaccines and ending 30 days after.
- •Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease.
- •History of /or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease or infection.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •Major congenital defects or serious chronic illness.
- •History of seizures or of any neurological disease at study entry.
- •Administration of immunoglobulins and/or any blood products since birth, or planned administration during the study period.
- •Acute disease at the time of enrolment.
结局指标
主要结局
Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values
时间窗: One month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9)
次要结局
- Number of subjects with serious adverse events(During the study period (Month 0 to Month 9))
- Immunogenicity with respect to the components of the study vaccine in terms of antibody titres greater than or equal to cut off values(One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).)
- Number of subjects with solicited and unsolicited adverse events(After each dose of the study vaccines (Month 0, Month 3 and Month 9) and overall)
- Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with vaccine response(One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).)
- Immunogenicity with respect to the components of the study vaccine in terms of antibody titers(Before the first dose (Month 0), one month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9).)
- Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values(Before the first dose ( Month 0 ))
研究者
相似试验
已完成
3 期
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyHaemophilus Influenzae Type b (Hib)PoliomyelitisHepatitis BTetanusDiphtheriaPertussisNCT01457508GlaxoSmithKline440
已完成
2 期
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered ConcomitantlyHaemophilus Influenzae Type b (Hib)PoliomyelitisDiphtheriaHepatitis BPertussisTetanusNCT01457495GlaxoSmithKline312
已完成
3 期
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm InfantsInfections, StreptococcalNCT00390910GlaxoSmithKline286
已完成
3 期
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in ChildrenInfluenzaNCT01196988GlaxoSmithKline3,027
已完成
3 期
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenRubellaMeaslesMumpsVaricellaNCT01506193GlaxoSmithKline716